Surgeons and burn centres
A randomised, controlled Phase III trial in severe burns is ongoing in burn centres across the EU and Switzerland, after Phase I and three Phase II studies.
See clinical development
denovoSkin™ is a two-layer skin graft made from the patient’s own cells, for people who need skin surgery after severe burns. It is grown in a closed, automated system and is now in Phase III, not yet approved.
Follow how it is made
Automation layer: a patented, fully closed, end-to-end production system, industrialised together with Tecan.
A small biopsy of healthy skin is harvested from the patient. Everything that follows starts from the patient’s own cells.
denovoSkin™ is an advanced therapy medicinal product, bioengineered in scalable quantities from a small biopsy of a patient’s healthy skin. CUTISS is developing it to replace autografting, today’s standard of care, which is limited by donor site shortage.
Orphan Drug Designation for the treatment of burns from Swissmedic, EMA and the FDA. denovoSkin™ is investigational and not yet approved.
“The key point is that it is a personalized bilayer graft.”Daniela Marino, co-founder and CEO, in UZH News, January 2026
A randomised, controlled Phase III trial in severe burns is ongoing in burn centres across the EU and Switzerland, after Phase I and three Phase II studies.
See clinical developmentSeries C of CHF 56 million in 2025, a manufacturing partnership with Tecan, and selection for EIC Accelerator support in November 2026.
Investor newsWhat denovoSkin™ is, how it is being studied and what it means that it is not yet approved, in plain language.
Information for patients
CUTISS manufactures denovoSkin™ in its certified GMP facility near Zurich and has built a first-in-class automation platform for scalable, decentralised production of personalised tissue.